1. Generics Bulletin
  2. >>Products

Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials

Formycon Collaborating With Partner Bioeq

 
• By Dean Rudge

Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Eylea represents one of the largest biological opportunities in the world. • Source: Shutterstock

The race to break into the $7.5bn global Eylea (aflibercept) market continues to gather pace, with Formycon AG and partner Bioeq IP AG announcing that patients are now enrolling in their Phase III clinical trial investigating the comparable efficacy, safety and immunogenicity of the firms’ FYB203 biosimilar aflibercept candidate.

An update to the clinicaltrials

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin